← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2004Last known activity
Apr 19, 2018
Acquired by Viracta Therapeutics, Inc. on Feb 25, 2021
Timeline
1990s
- Jun 1, 1998
Sunesis Pharmaceuticals— Founded
2020s
- Feb 25, 2021
Viracta Therapeutics, Inc.— Acquired By
Drugs by trial phase (7 distinct, 16 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Acute Disease
- Anemia, Refractory, with Excess of Blasts
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Small Cell
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasms
- Ovarian Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Small Cell Lung Carcinoma
- Syndrome
- Waldenstrom Macroglobulinemia
Recent trials (29)
- NCT03338348CollaboratorPhase 2Apr 19, 2018
- NCT03037645Study directorPhase 1/Phase 2Apr 28, 2017
- NCT03037645Lead sponsorPhase 1/Phase 2Apr 28, 2017
- NCT01980056CollaboratorPhase 1/Phase 2Oct 25, 2013
- NCT01893320CollaboratorPhase 1/Phase 2Jul 18, 2013
- NCT01191801Study directorPhase 3Dec 17, 2010
- NCT01191801Lead sponsorPhase 3Dec 17, 2010
- NCT00607997Study directorPhase 2Apr 1, 2008
- NCT00607997Lead sponsorPhase 2Apr 1, 2008
- NCT00519662Lead sponsorPhase 1Aug 1, 2007
- NCT00541866Study directorPhase 1/Phase 2Aug 1, 2007
- NCT00541866Lead sponsorPhase 1/Phase 2Aug 1, 2007
- NCT00519662Study directorPhase 1Aug 1, 2007
- NCT00446342Study directorPhase 1Feb 1, 2007
- NCT00446342Lead sponsorPhase 1Feb 1, 2007
Details
- Founded
- South San Francisco, CA, US Jun 1, 1998
- Last known activity
- Apr 19, 2018